496 related articles for article (PubMed ID: 25169020)
1. In vivo protection by broadly neutralizing HIV antibodies.
van Gils MJ; Sanders RW
Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
[TBL] [Abstract][Full Text] [Related]
2. Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012.
Girard MP; Picot V; Longuet C; Nabel GJ
Vaccine; 2013 Jun; 31(29):2979-83. PubMed ID: 23499518
[TBL] [Abstract][Full Text] [Related]
3. Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: differences from the human counterparts and implications for HIV-1 vaccine development.
Yuan T; Li J; Zhang Y; Wang Y; Streaker E; Dimitrov DS; Zhang MY
Vaccine; 2011 Sep; 29(40):6903-10. PubMed ID: 21807049
[TBL] [Abstract][Full Text] [Related]
4. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.
Parsons MS; Rouleau D; Routy JP; LeBlanc R; Grant MD; Bernard NF
AIDS; 2011 Jun; 25(10):1249-64. PubMed ID: 21516028
[TBL] [Abstract][Full Text] [Related]
5. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
van Gils MJ; Sanders RW
Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
[TBL] [Abstract][Full Text] [Related]
6. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.
Xu L; Pegu A; Rao E; Doria-Rose N; Beninga J; McKee K; Lord DM; Wei RR; Deng G; Louder M; Schmidt SD; Mankoff Z; Wu L; Asokan M; Beil C; Lange C; Leuschner WD; Kruip J; Sendak R; Kwon YD; Zhou T; Chen X; Bailer RT; Wang K; Choe M; Tartaglia LJ; Barouch DH; O'Dell S; Todd JP; Burton DR; Roederer M; Connors M; Koup RA; Kwong PD; Yang ZY; Mascola JR; Nabel GJ
Science; 2017 Oct; 358(6359):85-90. PubMed ID: 28931639
[TBL] [Abstract][Full Text] [Related]
7. Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?
Medina-Ramírez M; Sanders RW; Klasse PJ
Expert Rev Vaccines; 2014 Apr; 13(4):449-52. PubMed ID: 24606603
[TBL] [Abstract][Full Text] [Related]
8. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.
Stephenson KE; Wagh K; Korber B; Barouch DH
Annu Rev Immunol; 2020 Apr; 38():673-703. PubMed ID: 32340576
[TBL] [Abstract][Full Text] [Related]
9. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
Sadanand S; Suscovich TJ; Alter G
Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
[TBL] [Abstract][Full Text] [Related]
10. Germinal Center Lymphocyte Ratios and Successful HIV Vaccines.
Gonzalez-Figueroa P; Roco JA; Vinuesa CG
Trends Mol Med; 2017 Feb; 23(2):95-97. PubMed ID: 28089302
[TBL] [Abstract][Full Text] [Related]
11. HIV vaccine development--improving on natural immunity.
Johnston MI; Fauci AS
N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447
[No Abstract] [Full Text] [Related]
12. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.
Verkoczy L; Kelsoe G; Moody MA; Haynes BF
Curr Opin Immunol; 2011 Jun; 23(3):383-90. PubMed ID: 21524897
[TBL] [Abstract][Full Text] [Related]
13. On the benefits of sin: can greater understanding of the 1F7-idiotypic repertoire freeze enhance HIV vaccine development?
Parsons MS; Muller S; Kohler H; Grant MD; Bernard NF
Hum Vaccin Immunother; 2013 Jul; 9(7):1532-8. PubMed ID: 23571168
[TBL] [Abstract][Full Text] [Related]
14. The quest for an antibody-based HIV vaccine.
Haynes BF; Mascola JR
Immunol Rev; 2017 Jan; 275(1):5-10. PubMed ID: 28133795
[TBL] [Abstract][Full Text] [Related]
15. Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review.
Mahomed S; Garrett N; Baxter C; Abdool Karim Q; Abdool Karim SS
J Infect Dis; 2021 Feb; 223(3):370-380. PubMed ID: 32604408
[TBL] [Abstract][Full Text] [Related]
16. Virological features associated with the development of broadly neutralizing antibodies to HIV-1.
Moore PL; Williamson C; Morris L
Trends Microbiol; 2015 Apr; 23(4):204-11. PubMed ID: 25572881
[TBL] [Abstract][Full Text] [Related]
17. HIV Vaccines: One Step Closer.
Low MSY; Tarlinton D
Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies for HIV-1 prevention.
Julg B; Barouch DH
Curr Opin HIV AIDS; 2019 Jul; 14(4):318-324. PubMed ID: 31082819
[TBL] [Abstract][Full Text] [Related]
19. Progress in HIV vaccine development.
Hsu DC; O'Connell RJ
Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.
Rosenberg Y; Sack M; Montefiori D; Labranche C; Lewis M; Urban L; Mao L; Fischer R; Jiang X
PLoS One; 2015; 10(3):e0120451. PubMed ID: 25807114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
